NCT06339541

Brief Summary

The ACC Preclinical Research Platform for Precision Oncology is a retrospective and prospective observational study focused on the implementation and validation of the application of PDCM (Patient Derived Cancer Models) generated from tissues or cells of patients with neoplastic disease, as a tool to improve molecular and biological knowledge of tumours and to test the efficacy and sensitivity of pharmacological treatments.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 5, 2023

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

March 25, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 1, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

April 1, 2024

Status Verified

March 1, 2024

Enrollment Period

12 months

First QC Date

March 25, 2024

Last Update Submit

March 25, 2024

Conditions

Solid TumorHematologic Neoplasms

Outcome Measures

Primary Outcomes (2)

  • number of PDCM (patient derived cancer models)

    PDCM will be generated from tissues and cells

    12 months

  • number of Whole Exome Sequencing (WES) e RNA-seq performed

    WES and RNA seq will be performed on tissues and blood

    12 months

Secondary Outcomes (1)

  • number of PDCM shared within the network

    12 months

Eligibility Criteria

Age14 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients, including paediatric patients, with solid and haematological malignancies for whom tissue or tumour cell material is available.

You may qualify if:

  • Patients, including paediatric patients, with solid and haematological malignancies for whom tissue or tumour cell material is available.

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo

Candiolo, Turin, 10060, Italy

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Solid and haematological tumor tissues, blood

MeSH Terms

Conditions

Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Enzo Medico, MD

    Fondazione del Piemonte per l'Oncologia

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Enzo Medico, MD

CONTACT

+390119933234enzo.medico@ircc.it

Marco Asioli, BSc

CONTACT

+390119933463marco.asioli@ircc.it

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Oncogenomics

Study Record Dates

First Submitted

March 25, 2024

First Posted

April 1, 2024

Study Start

June 5, 2023

Primary Completion

June 1, 2024

Study Completion

December 1, 2024

Last Updated

April 1, 2024

Record last verified: 2024-03

Locations

IT(1)